BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 30, 2004
 |  BioCentury  |  Emerging Company Profile

Scancell: Apoptosis now

Many companies developing antibody-based cancer therapies identify antibodies that either mark the cancer site for destruction by the body's immune mechanisms, or act as a vector for chemotherapy to target the area. By contrast, Scancell Ltd. develops antibodies that directly kill the cells by inducing apoptosis.

As a second strategy, the company uses human antibodies to generate ImmunoBodies, fusion proteins in which the antibody carries T cell epitopes from tumor antigens. These ImmunoBodies are used as cancer vaccines specifically targeting dendritic cells in vivo, a trick that Scancell says many others have failed to accomplish to date.

"We are looking for specific cancer antigens that send cells directly into apoptosis when targeted by antibodies," said Lindy Durrant, CSO and founder of the company. "We have access to a broad range of primary tumor tissues, and a proprietary screen to identify apoptosis-inducing antibodies. This has provided us with a pipeline of 31 antibodies,...

Read the full 757 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >